Talk:Afoxolaner
| This is the talk page for discussing improvements to the Afoxolaner article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
 | This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Afoxolaner.
|
Elimination half-life is NOT 14 hours
editWikipedia now says:
Elimination half-life: 14 hours
This can't be right, not even close. The drug is given every 30 days to dogs.
For toxicology what is important is elimination half-life in BLOOD. This can't be 14 hours, because afoxolaner binds tightly to plasma proteins. How are plasma proteins eliminated and what is half-life of plasma proteins?
For efficacy against Ticks what is important is elimnation half-life in SKIN? Which is likely longer than in blood.
Legal status is incorrect, as FrontPro is OTC drug in Europe
editWikipedia claims:
Legal status CA: ℞-only US: ℞-only EU: Rx-only OTC (RU)
With so many errors in this Wikipedia article, can we trust even other information on this page?
For example Frontpro 136mg is over-the-counter drug for 25-50kg dogs in European Union. No precription is required, sold at pharmacy for example in Finland.
Afoxolaner was a prescription-only drug and prescription-only brands of this drug still exist.
Neurological side effect for Dogs is a major concern
editNeurological side effect for Dogs is much more common than vet drug manufacturers claim in product labels.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738705/ 2020 Nov.
A veterinarian and pet owner survey (Project Jake) examined the use and safety of isoxazoline parasiticides given to dogs.
58% (1594) had been treated with some parasiticide for flea control, and of those that received a parasiticide, the majority, or 83% (1,325), received an isooxazoline. When any flea treatment was given, AE were reported for 66.6% of respondents, with no apparent AE noted for 36.1%.
Survey responders did not indicate the Recovery Status from neurological effects. However, several isolated reports (private communications with the authors of which 3 are veterinarians have indicated extended long‐term neurologic signs with InComplete amelioration).
With respect to pet age, serious AE showed death reported in about 60% of dogs older than 5 years with seizures in more than 50% of dogs older than 5 years.
The most serious AE as stated in the EMA cumulative reports were observed at 0–24 hr after the first dose, and then again after the second and third doses.